Umbilical Cord Blood Banking Market Size, Share, Growth, Trends, and Global Industry Analysis: By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection, and Transportation), By Storage type (Private Umbilical Cord Blood Bank and Public Umbilical Cord Blood Bank), By Application (Bone Marrow Failure Syndrome, Metabolic Disorder, Leukemia, Immune Deficiencies, Lymphoma, and Others) and Region Forecast 2019-2030  

Umbilical Cord Blood Banking Market size was valued at US$ 1,467.2 million in 2023 and growing at a CAGR of 13.6% from 2024-2030. The market is fuelled by several key factors such as rising awareness of stem cell therapies, growing disposable income, expansion of treatable diseases, and government initiatives. Increased public awareness of the potential of stem cell therapies for treating various diseases like leukemia, lymphoma, and genetic disorders is increasing market growth. As disposable incomes rise, particularly in developing countries, parents are more willing to invest in their children's future health, including cord blood banking. Research is continuously expanding the number of diseases treatable with cord blood stem cells, making the option more attractive. Supportive government policies and initiatives in some countries are promoting cord blood banking. Storing cord blood for extended periods can be expensive, deterring some parents. Despite the growth, awareness about cord blood banking remains limited in some regions. Ethical concerns surround the use of cord blood from public banks and the potential for commercialization.

The regulatory landscape for cord blood banking varies globally, creating uncertainty for some potential users. Overall, the market presents a promising outlook with increasing awareness, expanding applications, and technological advancements. Technological advancements, increased public-private partnerships, a growing focus on personalized medicine, and expansion into emerging markets are the opportunities in the market that provide significant market growth in umbilical cord blood banking. However, addressing cost concerns, ethical considerations, and regulatory variations will be crucial for sustained growth

Key Developments

• In April 2023, the FDA approved Omisirge (by Gamida Cell Ltd.) a modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils in the body and reduce the risk of infection following stem cell transplantation.
• In March 2017, LifeCell launched Baby Cord Share, Community Stem Cell banking to address the need for creating a large inventory of stem cells in the country.
• In May 2023: A major US$ 54 billion investment was made by the American medical clinic StemCures to build a stem cell manufacturing lab in a state in India. The possibilities of umbilical cord blood banking in India and the increased interest in stem cell research are reflected in this venture.
• In December 2023: The China Marrow Donor Program and the Shanghai Cord Blood Bank worked together to release an app. By helping to find compatible donors from cord blood banks, this software improves the effectiveness of using cord blood and transplantation.